New York, United States
Apertura Gene Therapy, established in 2021, is a biotechnology firm focused on revolutionizing gene therapy by addressing the limitations of existing genetic medicine. Its slogan, "Bringing the Future of Gene Therapy into Focus," captures the company's vision. Situated at the Cure in New York City, Apertura is developing next-generation AAV gene therapies by innovating in capsids, regulatory elements, and payloads.
The company's strong foundation is based on technologies from the Broad Institute and Harvard University. It is supported by investments from Deerfield Management Company. Apertura received a $67.00M Series A investment in April 2022, highlighting significant interest in its potential to transform treatments for debilitating diseases with few options currently.
The firm operates within the biotechnology and healthcare industries in the United States, offering promising, cutting-edge solutions that leverage academic innovation with practical applications meant to enhance patient outcomes.
